烧钱上市的康方生物,补血“创新药”盈利未知

中访网财经
Dec 07, 2020

公开资料显示,康方生物科技成立于2012年,是一家临床阶段生物制药公司,专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求,运营主体为中山康方生物医药有限公司。主要专注于肿瘤学,免疫学和其他治疗领域。目前,集团正研发创新抗体药物涉及20多个药物开发项目,其中12个抗体处于临床阶段。其中,肿瘤学是公司专注的治疗领域之一,处于临床开发后期阶段的产品包括PD-1/CTLA-4双特异性抗体、PD-1...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10